How IR sleuthing has evolved from art to science
Catherine Forte remembers the 'old days'. 'We would pore over reams of Technimetrics listings, highlighting any fund manager running enough money to fit our investment parameters,' recalls the IR veteran, now associate director of IR at biotech firm Genzyme. 'Investment styles such as growth and value were not an issue. Afterward, we would consult the Nelson's books to read the investment manager profile, hoping it was up to date. That's how you made targeting assessments.' Since that time
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495